Endocrine disruptors and other inhibitors of 11β-hydroxysteroid dehydrogenase 1 and 2: Tissue-specific consequences of enzyme inhibition. Issue 155 (January 2016)

• Record Type: Journal Article
• Authors: Vitku, Jana; Starka, Luboslav; Bicikova, Marie; Hill, Martin; Heracek, Jiri; Sosvorova, Lucie; Hampl, Richard
• Is Part Of: Journal of steroid biochemistry and molecular biology. Issue 155 Part B(2016)
• Page Start: 207
• Page End: 216
• Publication Date: 2016-01
• Subjects: 11β-hydroxysteroid dehydrogenase -- Inhibitor -- Endocrine disruptor -- Testis -- Colon -- Adipose tissue -- Brain -- Placenta; Steroid hormones -- Periodicals; Biochemistry -- Periodicals; Hormones -- Periodicals; Molecular Biology -- Periodicals; Hormones stéroïdes -- Périodiques; Steroid hormones; Periodicals; 572.579
• DOI: 10.1016/j.jsbmb.2014.07.007
• Languages: English
• ISSNs: 0960-0760

Abstract

Highlights: 1βHSD isozymes can be modulated by several EDs and therapeutics. They may possess adverse or beneficial effects. Inhibition of 11βHSD in testes and placenta enhance glucocorticoids effects. Inhibition of 11βHSD2 may influence the growth of colon adenoma. 11βHSD inhibition has impact on obesity, diabetes, colon and brain disorders. Abstract: Numerous chemicals in the environment have the ability to interact with the endocrine system. These compounds are called endocrine disruptors (EDs). Exposure to EDs represents one of the hypotheses for decreasing fertility, the increased risk of numerous cancers and obesity, metabolic syndrome and type 2 diabetes. There are various mechanisms of ED action, one of which is their interference in the action of 11β-hydroxysteroid dehydrogenase (11βHSD) that maintains a balance between active and inactive glucocorticoids on the intracellular level. This enzyme has two isoforms and is expressed in various tissues. Inhibition of 11βHSD in various tissues can have different consequences. In the case of EDs, the results of exposure are mainly adverse; on the other hand pharmaceutically developed inhibitors of 11βHSD type 1 are evaluated as an option for treating metabolic syndrome, as well as related diseases and depressive disorders. This review focuses on the effects of 11βHSD inhibitors in the testis, colon, adipose tissue, kidney, brain and placenta.